CHICAGO, IL—Low-dose coronary alteplase infused early after PCI does not reduce the likelihood of microvascular obstruction (MVO) in ST-segment elevation MI, the T-Time trial suggests. Colin Berry, MD ...

The effects and risks of the use of intravenous thrombolysis between 4.5 and 24 hours after the onset of a posterior circulation ischemic stroke are not well studied. In a trial conducted in China, we ...

PRAGUE, Czech Republic — A 0.4-mg/kg bolus dose of tenecteplase (TNKase, Genentech) was associated with functional outcomes and safety similar to those seen with the standard of care, alteplase ...

Acute ischemic stroke accounts for about 87% of all stroke cases worldwide, necessitating swift action to restore blood flow and minimize neurological damage. Tenecteplase and Alteplase are key ...

Intravenous alteplase is the only approved treatment for acute ischemic stroke. Tenecteplase, a genetically engineered mutant tissue plasminogen activator, is an alternative thrombolytic agent. In ...

Switching from alteplase to tenecteplase as the thrombolytic used routinely for acute ischemic stroke is having multiple benefits for one US hospital system. Tenecteplase was developed as a more ...

When opting for a reperfusion strategy for STEMI that includes fibrinolytics, fibrin-specific agents combined with parenteral anticoagulants are the best choice, a network meta-analysis affirms.

DALLAS, Feb. 1, 2024 — Compared with the standard clot-busting medication alteplase, the newer clot-buster tenecteplase may offer a safe, effective and simpler way to treat ischemic (clot-caused) ...

In the UK, four thrombolytic agents are licensed and available to treat AMI. All act by promoting the activity of circulating plasminogen. There is a long history of use of one, streptokinase, whereas ...

NEW ORLEANS -- Tenecteplase in recent years outpaced alteplase as the stroke thrombolytic of choice at one large hospital system, despite shrinking cost savings, a researcher reported here. In 2021, ...